drugset / Trial / NCT03857256
Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.
Phase 2
Completed
263 enrolled
Montreal Heart Institute
Ceapro Inc. · collabThe Montreal Health Innovations Coordinating Center (MHICC) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to evaluate the effects of adding beta-glucan (1.5 g, 3 g or 6 g daily) administered three times a day (TID) in divided doses, to atorvastatin (10 mg - 20 mg) once a day or an equivalent dose of another statin on heart disease lipid risk factors.
Timeline
- Start
- 2019-05-31
- Primary completion
- 2021-08-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | beta-glucan | Other / unclassified | 1.5 g | — |
| Comparator | beta-glucan | Other / unclassified | 3 g | — |
| Comparator | beta-glucan | Other / unclassified | 6 g | — |